GENE ONLINE|News &
Opinion
Blog

2021-06-02| In-DepthInterviews

The Maturation of Blood-Based Diagnostics to Nip Cancers in the Bud: An Interview with Dr. Jimmy Lin

by Rajaneesh K. Gopinath
Share To
The war against cancer is far from over, but modern medicine has made significant progress in winning some critical battles. Thanks to the rise of new modalities, cancer diagnosis and treatment have seen practice-changing advances. Liquid biopsy, the latest entrant to precision oncology, enables the screening of cancer prevalence and detects multiple cancers with a single blood test. However, there is merit in choosing to tackle one cancer at a time using a multi-pronged approach, says Dr. Jimmy Lin, Chief Scientific Officer of Freenome.

It's free! Log in now to read

LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!